N-Propyl-L-asparaginsaeure

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-Propyl-L-asparaginsaeure
• 英文别名: (2S)-2-(propylamino)butanedioic acid
• 化学式: C₇H₁₃NO₄
• 分子量: 175.185
• InChiKey: JDISYLXGXNPIPL-YFKPBYRVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.5
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  86.6
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  L-天门冬氨酸 、 丙醛 在 platinum(IV) oxide sodium hydroxide 、 氢气 作用下， 生成 N-Propyl-L-asparaginsaeure
  参考文献：
  名称：

  Watkins,J.C., Journal of medicinal and pharmaceutical chemistry, 1962, vol. 5, p. 1187 - 1199

  摘要：

  DOI：

文献信息

• AMPK ACTIVATORS
  申请人：Kallyope, Inc.

  公开号：US20220002317A1

  公开（公告）日：2022-01-06

  This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists, super agonists, full agonists, or partial agonists.

  这份披露至少部分针对AMPK激活剂，用于治疗与AMPK相关的疾病或疾病。在某些实施例中，该疾病或疾病与肠-脑轴有关。在某些实施例中，该疾病或疾病与有漏肠屏障引起的全身感染和炎症有关。在某些实施例中，AMPK激活剂是肠道限制性化合物。在某些实施例中，AMPK激活剂是激动剂、超激动剂、全激动剂或部分激动剂。
• Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer
  申请人：BOSTON BIOMEDICAL, INC.

  公开号：US10183925B2

  公开（公告）日：2019-01-22

  The present invention provides compounds represented by formula (1A), or pharmaceutically acceptable salts. Compounds represented by formula (1A), or pharmaceutically acceptable salts thereof, wherein A1 and A2 are identical or different, and each independently —C(═O) B, —C(═O)CR3AR3BB, —CO2B, —C(═S)OB, —CONR3CB, —C(═S)NR3CB, a hydrogen atom, or the like, wherein A1 and A2 are not both hydrogen atoms, wherein B is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocyclic group, an optionally substituted 3- to 12-membered cyclic amino group, or a group represented by the following formula (B), wherein the 3- to 12-membered monocyclic or polycyclic heterocyclic group and the 3- to 12-membered cyclic amino group have at least one or more secondary nitrogen atoms in the ring; R1 is a hydrogen atom or the like; R2A, R2B, R2C, and R2D are identical or different, and each independently a hydrogen atom or the like; and R8 is alkyl. wherein * denotes a bonding position.

  本发明提供了式(1A)代表的化合物或其药学上可接受的盐。由式(1A)代表的化合物或其药学上可接受的盐，其中A1和A2相同或不同，且各自独立地为-C(═O)B、-C(═O)CR3AR3BB、-CO2B、-C(═S)OB、-CONR3CB、-C(═S)NR3CB、氢原子或类似物，其中A1和A2并非都是氢原子、其中 B 是任选取代的 3 至 12 元单环或多环杂环基团，任选取代的 3 至 12 元环状氨基基团，或下式（B）所代表的基团，其中 3 至 12 元单环或多环杂环基团和 3 至 12 元环状氨基基团在环中至少有一个或多个仲氮原子；R1为氢原子或类似物；R2A、R2B、R2C 和 R2D 相同或不同，且各自独立地为氢原子或类似物；以及 R8 为烷基。 其中 * 表示键合位置。
• WATER-SOLUBLE PRODRUGS
  申请人：BOSTON BIOMEDICAL, INC.

  公开号：US20180111914A1

  公开（公告）日：2018-04-26

  The present invention provides compounds represented by formula (1A), or pharmaceutically acceptable salts. Compounds represented by formula (1A), or pharmaceutically acceptable salts thereof, wherein A 1 and A 2 are identical or different, and each independently —C(═O) B, —C(═O)CR 3A R 3B B, —CO 2 B, —C(═S)OB, —CONR 3C B, —C(═S)NR 3C B, a hydrogen atom, or the like, wherein A 1 and A 2 are not both hydrogen atoms, wherein B is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocyclic group, an optionally substituted 3- to 12-membered cyclic amino group, or a group represented by the following formula (B), wherein the 3- to 12-membered monocyclic or polycyclic heterocyclic group and the 3- to 12-membered cyclic amino group have at least one or more secondary nitrogen atoms in the ring; R 1 is a hydrogen atom or the like; R 2A , R 2B , R 2C , and R 2D are identical or different, and each independently a hydrogen atom or the like; and R 8 is alkyl. wherein * denotes a bonding position.
• SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER
  申请人：BOSTON BIOMEDICAL, INC.

  公开号：US20190084955A1

  公开（公告）日：2019-03-21

  The present invention provides compounds represented by formula (1A), or pharmaceutically acceptable salts. Compounds represented by formula (1A), or pharmaceutically acceptable salts thereof, wherein A 1 and A 2 are identical or different, and each independently —C(═O)B, —C(═O)CR 3A R 3B B, —CO 2 B, —C(═S)OB, —CONR 3C B, —C(═S)NR 3C B, a hydrogen atom, or the like, wherein A 1 and A 2 are not both hydrogen atoms, wherein B is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocyclic group, an optionally substituted 3- to 12-membered cyclic amino group, or a group represented by the following formula (B), wherein the 3- to 12-membered monocyclic or polycyclic heterocyclic group and the 3- to 12-membered cyclic amino group have at least one or more secondary nitrogen atoms in the ring; R 1 is a hydrogen atom or the like; R 2A , R 2B , R 2C , and R 2D are identical or different, and each independently a hydrogen atom or the like; and R 8 is alkyl. wherein * denotes a bonding position.
• Watkins,J.C., Journal of medicinal and pharmaceutical chemistry, 1962, vol. 5, p. 1187 - 1199
  作者：Watkins,J.C.

  DOI：——

  日期：——